Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT05835986
- Locations
- 🇹🇭
Ramathibodi Hospital, Mahidol Uni ; Allergy, Immunology & Rheumatology, Dept of Medicine, Bangkok, Thailand
🇩🇪Charité Research Organisation GmbH, Berlin, Germany
🇩🇪Universitätsklinikum Duesseldorf; Klinik fuer Nephrologie und Rheumatologie, Düsseldorf, Germany
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT05808764
- Locations
- 🇨🇦
Children'S Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇺🇸Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States
🇳🇱UMC Utrecht, Utrecht, Netherlands
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT05805501
- Locations
- 🇺🇸
Vanderbilt University Medical Center; Vanderbilt University, Nashville, Tennessee, United States
🇺🇸EMORY UNIVERSITY; Bone Marrow & Stem Cell Transplant Center, Atlanta, Georgia, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 428
- Registration Number
- NCT05797610
- Locations
- 🇲🇾
Hospital Kuala Lumpur, Kuala Lumpur, FED. Territory OF Kuala Lumpur, Malaysia
🇵🇱SCM Clinic - Prywatny Szpital Specjalistyczny, Kraków, Poland
🇲🇾University Malaya Medical Centre, Kuala Lumpur, FED. Territory OF Kuala Lumpur, Malaysia
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT05789082
- Locations
- 🇺🇸
MD Anderson Cancer Center; Oncology, Houston, Texas, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT05775289
- Locations
- 🇲🇽
ONCARE Viaducto Napoles, Ciudad de México, Mexico CITY (federal District), Mexico
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain
🇦🇺Monash Health, Clayton, Victoria, Australia
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT05769959
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT05763576
- Locations
- 🇨🇳
Chang Gung Medical Foundation Linkou Branch, Taoyuan City, Taiwan
🇹🇭Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
🇨🇳Taichung Veterans General Hospital, Xitun Dist., Taiwan
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 129
- Registration Number
- NCT05704361
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇵🇱Regionalny Szpital Specjalistyczny im. W. Bieganskiego; Oddzial Neurologiczny, Grudzi?dz, Poland
🇵🇱SPSK nr 1; Klinika Neurologii, Zabrze, Poland
Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT05694013
- Locations
- 🇦🇺
Latrobe Regional Hospital, Traralgon, Victoria, Australia
🇦🇹Klinikum Klagenfurt am Wörtersee, Klagenfurt am Worthersee, Austria
🇦🇹Klinikum Klagenfurt am Wörtersee; Abt.Gastroenterologie&Hepatologie,Endokrinologie, Klagenfurt, Austria